Common Genomic Response in Different Mouse Models of &bgr;-Adrenergic–Induced Cardiomyopathy

Background—Although &bgr;-adrenergic receptor (AR) blockade therapy is beneficial in the treatment of heart failure, little is known regarding the transcriptional mechanisms underlying this salutary action. Methods and Results—In the present study, we screened mice overexpressing Gs&agr;, &bgr;1AR, &bgr;2AR, or protein kinase A to test if a common genomic pathway exists in different models with enhanced &bgr;-adrenergic signaling. In mice overexpressing Gs&agr;, differentially expressed genes were identified by mRNA profiling. In addition to well-known markers of cardiac hypertrophy (atrial natriuretic factor, CARP, and &bgr;-myosin heavy chain), uncoupling protein 2 (UCP2), a protein involved in the control of mitochondrial membrane potential, and four-and-a-half LIM domain protein-1 (FHL1), a member of the LIM protein family, were predicted to be upregulated. Upregulation of these genes was confirmed by quantitative reverse transcriptase–polymerase chain reaction at all time points tested during the development of cardiomyopathy in mice overexpressing Gs&agr;. In mice overexpressing &bgr;1AR, &bgr;2AR, or protein kinase A, increased UCP2 and FHL1 expression was also observed at the onset of cardiomyopathy. &bgr;AR blockade treatment reversed the cardiomyopathy and suppressed the increased expression of UCP2 and FHL1 in mice overexpressing Gs&agr;. Conclusions—UCP2 and FHL1 are important candidate genes that correlate with the development of &bgr;AR-induced cardiomyopathy in different mouse models with enhanced &bgr;AR signaling. In addition to preserving cardiac function, &bgr;AR blockade treatment also prevents the genomic regulation that correlates with the onset of heart failure.

[1]  E. Olson,et al.  Dilated Cardiomyopathy and Sudden Death Resulting From Constitutive Activation of Protein Kinase A , 2001, Circulation research.

[2]  A. Marian,et al.  Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. , 2001, Journal of the American College of Cardiology.

[3]  W. Koch,et al.  Transgenic studies of cardiac adrenergic receptor regulation. , 2001, The Journal of pharmacology and experimental therapeutics.

[4]  S. Vatner,et al.  Gene program for cardiac cell survival induced by transient ischemia in conscious pigs , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Port,et al.  Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. , 2001, Journal of molecular and cellular cardiology.

[6]  J. Simons,et al.  Open systems: panoramic views of gene expression. , 2001, Journal of immunological methods.

[7]  E. Lakatta,et al.  The β2-Adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-Dependent coupling to phosphatidylinositol 3'-kinase , 2000 .

[8]  B. Miroux,et al.  Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production , 2000, Nature Genetics.

[9]  Qiang Zhou,et al.  Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system , 2000, Mechanisms of Development.

[10]  M. Raynolds,et al.  Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. , 2000, Journal of molecular and cellular cardiology.

[11]  G. Dorn,et al.  Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. , 2000, Circulation.

[12]  E. Lakatta,et al.  Recent Advances in Cardiac b2-Adrenergic Signal Transduction , 1999 .

[13]  D. Sanchís,et al.  The mitochondrial uncoupling protein-2: current status. , 1999, The international journal of biochemistry & cell biology.

[14]  J. Hoek,et al.  Mitochondrial Uncoupling: Role of Uncoupling Protein Anion Carriers and Relationship to Thermogenesis and Weight Control “The Benefits of Losing Control” , 1999, Journal of bioenergetics and biomembranes.

[15]  S. Vatner,et al.  β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse , 1999 .

[16]  J. W. Simpson,et al.  Gene expression analysis by transcript profiling coupled to a gene database query , 1999, Nature Biotechnology.

[17]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Vatner,et al.  Apoptosis of Cardiac Myocytes in Gsα Transgenic Mice , 1999 .

[19]  G. Shipley,et al.  Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy , 1998, Nature Medicine.

[20]  M. Packer,et al.  Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. , 1998, Circulation.

[21]  M. Waye,et al.  Chromosomal mapping, tissue distribution and cDNA sequence of four-and-a-half LIM domain protein 1 (FHL1). , 1998, Gene.

[22]  K P Fung,et al.  A genome-based resource for molecular cardiovascular medicine: toward a compendium of cardiovascular genes. , 1997, Circulation.

[23]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.

[24]  C. Heid,et al.  A novel method for real time quantitative RT-PCR. , 1996, Genome research.

[25]  M. Morgan,et al.  Slim defines a novel family of LIM-proteins expressed in skeletal muscle. , 1996, Biochemical and biophysical research communications.

[26]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[27]  Y. Ishikawa,et al.  Overexpression of Gs alpha protein in the hearts of transgenic mice. , 1995, The Journal of clinical investigation.

[28]  R. Lefkowitz,et al.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. , 1994, Science.

[29]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[30]  H. Rindt,et al.  In vivo analysis of the murine beta-myosin heavy chain gene promoter. , 1993, The Journal of biological chemistry.

[31]  A. Angelini,et al.  Propranolol-induced changes in ventricular isomyosin composition in the rat. , 1985, American heart journal.

[32]  M. Lindhout,et al.  Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. , 2003, American journal of physiology. Heart and circulatory physiology.

[33]  E. Lakatta,et al.  The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. , 2000, Circulation research.

[34]  E. Lakatta,et al.  Recent advances in cardiac beta(2)-adrenergic signal transduction. , 1999, Circulation research.

[35]  S. Vatner,et al.  Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. , 1999, The Journal of clinical investigation.

[36]  S. Vatner,et al.  Apoptosis of cardiac myocytes in Gsalpha transgenic mice. , 1999, Circulation research.

[37]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.